부산대학교 도서관

Real-life data concerning dupilumab effectiveness and safety in adolescents (aged >= 12 to <18 years) with moderate to severe atopic dermatitis (AD) are rarely reported.1 In two adolescence studies, the phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open-label extension (LIBERTY AD PED-OLE)3 dupilumab produced significant improvement in signs and symptoms at Week 16, with a good safety profile. The issue of dupilumab therapy was under debate during COVID-19 pandemic first wave.4 In the Italian experience on 1576 patients under dupilumab treatment, 15 patients contracted SARS-CoV-2 infection with a good clinical outcome, confirming that dupilumab should be continued during the COVID-19 pandemic.5 Nevertheless, systematic studies are needed to evaluate the effect of dupilumab in patients with SARS-CoV-2 infection. Two of our patients (22.2%) achieved completely clear skin, compared with none of patients included in the previous trials.2,3 Additionally, we observed a greater improvement in patients with low BMI and high EASI at baseline. [Extracted from the article]